Dermatitis - Pipeline Review, H2 2015

Date: December 30, 2015
Pages: 445
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D1735B999F1EN
Leaflet:

Download PDF Leaflet

Dermatitis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Dermatitis - Pipeline Review, H2 2015’, provides an overview of the Dermatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Dermatitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dermatitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dermatitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dermatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Dermatitis Overview
Therapeutics Development
Dermatitis - Therapeutics under Development by Companies
Dermatitis - Therapeutics under Investigation by Universities/Institutes
Dermatitis - Pipeline Products Glance
Dermatitis - Products under Development by Companies
Dermatitis - Products under Investigation by Universities/Institutes
Dermatitis - Companies Involved in Therapeutics Development
Dermatitis - Therapeutics Assessment
Drug Profiles
Dermatitis - Recent Pipeline Updates
Dermatitis - Dormant Projects
Dermatitis - Discontinued Products
Dermatitis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Dermatitis, H2 2015
Number of Products under Development for Dermatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2015
Dermatitis - Pipeline by 3SBio Inc., H2 2015
Dermatitis - Pipeline by Abeome Corporation, H2 2015
Dermatitis - Pipeline by Accolade Pharma LLC, H2 2015
Dermatitis - Pipeline by Aclaris Therapeutics, Inc., H2 2015
Dermatitis - Pipeline by AlbireoPharma, H2 2015
Dermatitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015
Dermatitis - Pipeline by Almirall, S.A., H2 2015
Dermatitis - Pipeline by Amgen Inc., H2 2015
Dermatitis - Pipeline by Amorepacific Corporation, H2 2015
Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015
Dermatitis - Pipeline by AnaMar AB, H2 2015
Dermatitis - Pipeline by AnaptysBio, Inc., H2 2015
Dermatitis - Pipeline by AnGes MG, Inc., H2 2015
Dermatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015
Dermatitis - Pipeline by arGEN-X BV, H2 2015
Dermatitis - Pipeline by AskAt Inc., H2 2015
Dermatitis - Pipeline by Athenex, Inc., H2 2015
Dermatitis - Pipeline by Biomar Microbial Technologies, H2 2015
Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2015
Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2015
Dermatitis - Pipeline by Celgene Corporation, H2 2015
Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2015
Dermatitis - Pipeline by China Biologic Products, Inc., H2 2015
Dermatitis - Pipeline by ChironWells GmbH, H2 2015
Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015
Dermatitis - Pipeline by Convoy Therapeutics, Inc., H2 2015
Dermatitis - Pipeline by Creabilis SA, H2 2015
Dermatitis - Pipeline by Delenex Therapeutics AG, H2 2015
Dermatitis - Pipeline by Dermira Inc., H2 2015
Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2015
Dermatitis - Pipeline by Eisai Co., Ltd., H2 2015
Dermatitis - Pipeline by Eli Lilly and Company, H2 2015
Dermatitis - Pipeline by EpiPharm AG, H2 2015
Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Dermatitis - Pipeline by FAES Farma SA, H2 2015
Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2015
Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2015
Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
Dermatitis - Pipeline by GlycaNova Norway AS, H2 2015
Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2015
Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Dermatitis - Pipeline by Hapten Sciences, Inc., H2 2015
Dermatitis - Pipeline by Herantis Pharma Plc, H2 2015
Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2015
Dermatitis - Pipeline by ILiAD Biotechnologies, LLC, H2 2015
Dermatitis - Pipeline by IMMD Inc., H2 2015
Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Dermatitis - Pipeline by Immune Response BioPharma, Inc., H2 2015
Dermatitis - Pipeline by Inflamalps SA, H2 2015
Dermatitis - Pipeline by Japan Tobacco Inc., H2 2015
Dermatitis - Pipeline by Johnson & Johnson, H2 2015
Dermatitis - Pipeline by K-Stemcell Co., Ltd., H2 2015
Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2015
Dermatitis - Pipeline by LEO Pharma A/S, H2 2015
Dermatitis - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2015
Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2015
Dermatitis - Pipeline by Maruho Co., Ltd., H2 2015
Dermatitis - Pipeline by MedImmune, LLC, H2 2015
Dermatitis - Pipeline by Merck & Co., Inc., H2 2015
Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2015
Dermatitis - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015
Dermatitis - Pipeline by Novartis AG, H2 2015
Dermatitis - Pipeline by Nuvo Research Inc., H2 2015
Dermatitis - Pipeline by Orbis Biosciences, Inc., H2 2015
Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Dermatitis - Pipeline by Oxagen Limited, H2 2015
Dermatitis - Pipeline by Pfizer Inc., H2 2015
Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2015
Dermatitis - Pipeline by Pharmedartis GmbH, H2 2015
Dermatitis - Pipeline by Phosphagenics Limited, H2 2015
Dermatitis - Pipeline by ProCertus BioPharm Inc., H2 2015
Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
Dermatitis - Pipeline by Reata Pharmaceuticals, Inc., H2 2015
Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2015
Dermatitis - Pipeline by SK Chemicals Co., Ltd., H2 2015
Dermatitis - Pipeline by Spherium Biomed S.L., H2 2015
Dermatitis - Pipeline by Stemnion, Inc, H2 2015
Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015
Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2015
Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015
Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
Dermatitis - Pipeline by Vicore Pharma AB, H2 2015
Dermatitis - Pipeline by Vida Therapeutics Inc., H2 2015
Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015
Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
Dermatitis - Pipeline by Welichem Biotech Inc., H2 2015
Dermatitis - Pipeline by XBiotech USA, Inc., H2 2015
Dermatitis - Pipeline by Xencor, Inc., H2 2015
Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Dermatitis Therapeutics - Recent Pipeline Updates, H2 2015
Dermatitis - Dormant Projects, H2 2015
Dermatitis - Dormant Projects (Contd..1), H2 2015
Dermatitis - Dormant Projects (Contd..2), H2 2015
Dermatitis - Dormant Projects (Contd..3), H2 2015
Dermatitis - Dormant Projects (Contd..4), H2 2015
Dermatitis - Dormant Projects (Contd..5), H2 2015
Dermatitis - Dormant Projects (Contd..6), H2 2015
Dermatitis - Dormant Projects (Contd..7), H2 2015
Dermatitis - Dormant Projects (Contd..8), H2 2015
Dermatitis - Dormant Projects (Contd..9), H2 2015
Dermatitis - Dormant Projects (Contd..10), H2 2015
Dermatitis - Dormant Projects (Contd..11), H2 2015
Dermatitis - Dormant Projects (Contd..12), H2 2015
Dermatitis - Dormant Projects (Contd..13), H2 2015
Dermatitis - Discontinued Products, H2 2015
Dermatitis - Discontinued Products (Contd..1), H2 2015

LIST OF FIGURES

Number of Products under Development for Dermatitis, H2 2015
Number of Products under Development for Dermatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3SBio Inc.
Abeome Corporation
Accolade Pharma LLC
Aclaris Therapeutics, Inc.
AlbireoPharma
Aldeyra Therapeutics, Inc.
Almirall, S.A.
Amgen Inc.
Amorepacific Corporation
Anacor Pharmaceuticals, Inc.
AnaMar AB
AnaptysBio, Inc.
AnGes MG, Inc.
Aquinox Pharmaceuticals Inc.
arGEN-X BV
AskAt Inc.
Athenex, Inc.
Biomar Microbial Technologies
Blueberry Therapeutics Ltd
Brickell Biotech, Inc.
Celgene Corporation
ChemoCentryx, Inc.
China Biologic Products, Inc.
ChironWells GmbH
Chugai Pharmaceutical Co., Ltd.
Convoy Therapeutics, Inc.
Creabilis SA
Delenex Therapeutics AG
Dermira Inc.
Dr. August Wolff GmbH & Co. KG Arzneimittle
Eisai Co., Ltd.
Eli Lilly and Company
EpiPharm AG
F. Hoffmann-La Roche Ltd.
FAES Farma SA
Foamix Pharmaceuticals Ltd.
Fountain Biopharma Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GlycaNova Norway AS
Grupo Ferrer Internacional, S.A.
Han Wha Pharma Co., Ltd.
HanAll Biopharma Co., Ltd.
Hapten Sciences, Inc.
Herantis Pharma Plc
iCo Therapeutics Inc.
ILiAD Biotechnologies, LLC
IMMD Inc.
Immune Pharmaceuticals Inc.
Immune Response BioPharma, Inc.
Inflamalps SA
Japan Tobacco Inc.
Johnson & Johnson
K-Stemcell Co., Ltd.
LegoChem Biosciences, Inc
LEO Pharma A/S
Lixte Biotechnology Holdings, Inc.
Madam Therapeutics B.V.
Marinomed Biotechnologie GmbH
Maruho Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
NeoPharm Co., Ltd.
NovaLead Pharma Pvt. Ltd.
Novartis AG
Nuvo Research Inc.
Orbis Biosciences, Inc.
Otsuka Holdings Co., Ltd.
Oxagen Limited
Pfizer Inc.
Pharis Biotec GmbH
Pharmedartis GmbH
Phosphagenics Limited
ProCertus BioPharm Inc.
Provectus Biopharmaceuticals, Inc.
Reata Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Signum Dermalogix, Inc
SK Chemicals Co., Ltd.
Spherium Biomed S.L.
Stemnion, Inc
sterna biologicals Gmbh & Co KG
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
SWITCH Biotech LLC
Takeda Pharmaceutical Company Limited
Thesan Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Vicore Pharma AB
Vida Therapeutics Inc.
Vitae Pharmaceuticals, Inc.
VivaCell Biotechnology Espana S.L.
Welichem Biotech Inc.
XBiotech USA, Inc.
Xencor, Inc.
Ziarco Pharma Ltd
Skip to top


Dermatitis - Pipeline Review, H1 2015 US$ 1,600.00 Mar, 2015 · 381 pages
Contact Dermatitis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 69 pages
Contact Dermatitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 75 pages

Ask Your Question

Dermatitis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: